Pricing
  1. JP-listed companies
  2. TAIKO PHARMACEUTICAL CO., LTD.
  3. Financials
  4. Income before tax

TAIKO PHARMACEUTICAL CO., LTD. (4574)

Market cap
¥15.4B
P/E ratio
27.8x
Makes over-the-counter medicines like Seirogan and Cleverin infection control products, serving consumers and institutions across Japan and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Dec 31, 2025482-29.94%
Dec 31, 2024688-155.13%
Dec 31, 2023-1,248-62.77%
Dec 31, 2022-3,352-45.33%
Dec 31, 2021-6,131-212.40%
Dec 31, 20205,454+50.13%
Mar 31, 20203,633+92.73%
Mar 31, 20191,885+20.23%
Mar 31, 20181,568+11.38%
Mar 31, 20171,408+7.66%
Mar 31, 20161,307-52.91%
Mar 31, 20152,776+3.45%
Mar 31, 20142,684+121.49%
Mar 31, 20131,212+116.77%
Mar 31, 2012559

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat